Blood Vessel Inflammation After Durvalumab Treatment for Stage III Lung Cancer

Patient Info: Anonymized, Female, 70+ | Stage III

The lung cancer had responded well to chemoradiation and durvalumab, while treatment-related pneumonitis and vasculitis improved with corticosteroids and withdrawal or completion of durvalumab.

PubMed CentralRead more →

Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed CentralRead more →

Small-Cell Lung Cancer First Appeared as Rapidly Worsening Nerve Damage

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-Hu-positive; anti-CV2/CRMP5-positive; anti-SOX1-positive

Despite six cycles of carboplatin and etoposide and intensive treatment for the paraneoplastic neuropathy, her neurological condition progressed; after a thrombocytopenia-related brain haemorrhage, she entered palliative care and died within weeks.

PubMed CentralRead more →

Pleomorphic lung cancer responding to pembrolizumab plus chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >75%; EGFR negative; ROS1 negative; ALK fusion negative

Metastatic Site: right 8th rib, left adrenal gland

His general condition improved as the tumors shrank, and he remained well 7 months after diagnosis with maintenance pembrolizumab planned.

PubMed CentralRead more →

Multifocal stage IIIA lung adenocarcinoma responding to nivolumab

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: CK7-positive; TTF-1-positive; napsin-A-positive; PD-L1 85% positive.

The biopsied lung nodule nearly resolved after four nivolumab cycles, and the remaining pulmonary nodules were stable at 24 months.

PubMed CentralRead more →

Tomma Hargraves: Choosing to Help Other Patients after Surviving Lung Cancer

Patient Info: Tomma Hargraves | Stage IV

Metastatic Site: brain

After treatment and a later recurrence, Tomma went many years without further cancer treatment and became a patient navigator and advocate. She died on September 7, 2023.

Stage IV Non-Small Cell Lung Cancer: Tomma's Patient Story

Patient Info: Tomma Hargraves, Female | Stage IV

Metastatic Site: brain

After a later brain and lymph-node relapse was brought under control, Tomma had no further cancer treatment and remained active in survivorship advocacy. She died on September 7, 2023.

More than 10 years living with relapsing extensive-stage small cell lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Chromogranin-positive.

Metastatic Site: pleura; pancreas; left kidney and perinephric region

After five treatment lines and several metastatic relapses over more than 10 years, his latest irinotecan and carboplatin course produced another partial response and he was doing well at the last follow-up.

PubMed CentralRead more →

Late-onset mania revealed advanced small cell lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ACTH-producing tumor with ACTH 776 pg/mL and morning cortisol 206.8 micrograms/dL.

Metastatic Site: right lung; liver

He died a few months after diagnosis from aspiration pneumonia and multiorgan failure in the setting of rapidly deteriorating stage IV small cell lung cancer.

PubMed CentralRead more →

A reversible brain syndrome after chemotherapy for stage IIB lung cancer

Patient Info: Anonymized, Female, 60s | Stage II

Her seizure-related neurological findings resolved during hospitalization, and she was discharged without neurological symptoms after chemotherapy was stopped.

PubMed CentralRead more →

Small cell lung cancer found through a disabling paraneoplastic neuropathy

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-CRMP5 antibody-positive.

She completed chemotherapy and radiation and entered oncology follow-up, while the disabling sensory and motor neuropathy persisted and rehabilitation continued.

PubMed CentralRead more →

Lung Cancer: Keith's Survivor Story

Patient Info: Keith Medovich, Male, 60s

As of January 2020, Keith was rid of lung cancer after 2003 chemotherapy and radiation, but required ongoing management of severe late radiation-related airway stenosis with a custom patient-specific stent.

Cleveland ClinicRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Stage IV RET Non-Small Cell Lung Cancer: Sara's Patient Story

Patient Info: Sara Whitlock, Female, 40s | Stage IV

Biomarkers: RET fusion-positive NSCLC

Metastatic Site: Brain; abdomen; bowel

As of November 2019, Sara had Stage IV RET fusion-positive NSCLC with a long-term response and no signs of cancer while taking selpercatinib/LOXO-292 on a clinical trial, with ongoing monthly follow-up.

Cleveland ClinicRead more →

Stage IV ALK Non-Small Cell Lung Cancer: James's Patient Story

Patient Info: James “Rocky” Lagno, Male | Stage IV

Biomarkers: ALK-positive

Metastatic Site: brain

After starting ceritinib through compassionate use, Rocky reported stable disease from the middle of 2013 with quality of life close to his pre-diagnosis level, while recognizing that he was not in remission or cancer-free.

Stage IV Non-Small Cell Lung Cancer: Donna's Patient Story

Patient Info: Donna Fernandez, Female, 50s | Stage IV

While receiving nivolumab on a Phase III trial, Donna’s tumors remained present but stopped growing, and she was able to return to an active daily life.

Stage III Non-Small Cell Lung Cancer: Renee's Patient Story

Patient Info: Renee Shine, Female, 60s | Stage III

Renee’s tumor responded to pembrolizumab, and she remained on treatment through the clinical trial while describing herself as thriving.

Stage IV EGFR Non-Small Cell Lung Cancer: Ginger's Patient Story

Patient Info: Ginger Tam, Female | Stage IV

Biomarkers: EGFR mutation

Ginger lived for more than 5 years with metastatic lung cancer while receiving multiple research-driven treatments. She died on February 10, 2018.

Long-Term Nivolumab Response With Thyroid and Adrenal Side Effects

Patient Info: Anonymized, Male, 50s | Stage IV

Nivolumab remained ongoing at course 82, tumor burden had fallen to one-fifth of baseline, and no disease progression was documented.

PubMed CentralRead more →

Nivolumab-Related Myocarditis and Heart Block in Metastatic Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: left adrenal gland

He stabilized after high-dose steroids and pacemaker implantation after nivolumab was permanently stopped.

PubMed CentralRead more →

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed CentralRead more →

Speech and Swallowing Support After Lung Cancer Relapse

Patient Info: Anonymized, 70+ | Stage Metastatic/Advanced

Metastatic Site: both lungs

The lung cancer relapsed with mediastinal and supraclavicular lymph-node involvement and metastases in both lungs. Ongoing speech and swallowing support prevented reported dysphagia complications.

PubMed CentralRead more →

Small Cell Lung Cancer With SIADH in a 45-Year-Old Man Receiving Chemotherapy

Patient Info: Anonymized, male, 40s

After brain and pelvic metastases developed through successive chemotherapy lines, care shifted to a palliative approach and he died approximately 1 year after diagnosis.

PubMed CentralRead more →

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed CentralRead more →